脐血单个核细胞移植对帕金森病的临床疗效研究

目的观察经寰枕间隙侧方穿刺术移植人脐血单个核细胞(hUCB-MNCs)治疗帕金森病(PD)的临床疗效。方法选取聊城市人民医院神经内科经寰枕间隙侧方穿刺术移植hUCB-MNCs治疗的31例PD患者,于治疗前及治疗后1、3、6、12个月,采用统一帕金森评估量表(UPDRS)第Ⅱ部分、第Ⅲ部分和帕金森非运动症状评价量表(NMSS)、匹兹堡睡眠质量指数量表(PSOI)对患者进行评分,并记录左旋多巴等效剂量(LED)。采用重复测量资料方差分析对治疗前后多个时间点的评分及左旋多巴等效剂量进行比较,两两比较采用Bonferroni检验。结果(1)与治疗前比较,治疗后3、6、12个月UPDRSⅡ评分(17.75±6.81)分比(13.67±5.62)分、(12.54±4.39)分、(10.41±4.31)分]均降低;治疗后3、6、12个月UPDRSⅢ评分(28.53±14.75)分比(21.65±10.11)分、(19.37±9.26)分、(16.12±7.44)分]亦均降低,差异有统计学意义(P<0.05)。(2)与治疗前比较,治疗后1、3、6、12个月NMSS评分(58.94±35.74)分比(50.27±31.06)分、(41.38±28.25)分、(38.42±25.73)分、(36.15±24.56)分]均降低,差异有统计学意义(P<0.05)。PSOI评分亦有相同变化趋势。(3)与治疗前比较,治疗后6、12个月LED(629.57±205.33)mg/d比(435.54±160.62)mg/d、(300.71±135.83)mg/d]下降,差异有统计学意义(P<0.05)。结论经寰枕间隙侧方穿刺术移植hUCB-MNCs治疗能改善PD患者的运动及非运动症状,延缓病情的进展。

Clinical effects of umbilical cord blood mononuclear cell transplantation on Parkinson's disease

ObjectiveTo observe the clinical efficacy of human umbilical cord blood mononuclear cell transplantation treatment for Parkinson's disease by lateral atlanto-occipital space puncture. MethodsThirty-one Parkinson's disease patients from the Department of Neurology in Liaocheng People's Hospital were treated with human umbilical cord blood mononuclear cell transplantation by lateral atlanto-occipital space puncture. The Unified Parkinson's Disease Rating Scale (UPDRS) Ⅱ/Ⅲ, Non-Motor Symptoms Scale for Parkinson's Disease (NMSS) , and Pittsburgh sleep quality index (PSQI) were used for assessment of each patient before treatment and 1, 3, 6 and 12 months after treatment. Repeated measures analysis of variance was used to compare the scores of multiple time points before and after treatment and the Bonferroni test was used to compare the scores of each time in pairs. Results(1) Compared with that before treatment, the score of UPDRS-Ⅱ in month 3, 6, 12 after treatmentwere decreased (17.75±6.81) points vs (13.67±5.62) points, (12.54±4.39) points, (10.41±4.31) points]; the score of UPDRS-III in month 3, 6, 12 after treatment were also decreased (28.53±14.75) points vs (21.65±10.11) points, (19.37±9.26) points, (16.12±7.44) points], and the differences were statistically significant (P < 0.05) . (2) Compared with that before treatment, the score of NMSS in month 1, 3, 6, 12 after treatment were decreased (58.94±35.74) points vs (50.27±31.06) points, (41.38±28.25) points, (38.42±25.73) points, (36.15±24.56) points], and the differences were statistically significant (P < 0.05) . The score of PSOI also showed a same change trend. (3) Compared with that before treatment, the LED in month 6, 12 after treatment were decreased (629.57±205.33) mg/d vs (435.54±160.62) mg/d, (300.71±135.83) mg/d], and the differences were statistically significant (P < 0.05) . ConclusionsHuman umbilical cord blood mononuclear cell transplantation treatment for Parkinson's disease by lateral atlanto-occipital space puncture can improve the motor and non-motor symptoms and retard the progression of the disease.